New data shows long-term durability of Zolgensma treatment in patients with spinal muscular atrophy

AveXis announced interim long-term follow-up data from the Phase 1 trial of Zolgensma that showed durability of the one-shot gene therapy in patients with spinal muscular atrophy (SMA) Type 1 nearly four years after treatment. This data was presented during the 2019 American Academy of Neurology (AAN) Conference. Zolgensma is designed to address the genetic root cause of SMA...

Researchers uncover mechanism blocking regeneration of the retina

A discovery opens the possibility of one day restoring loss of vision by activating the retina’s ability to regenerate. Researchers at Baylor College of Medicine, the Cardiovascular Research Institute and the Texas Heart Institute reveal in the journal Cell Reports that although the mammalian retina – a layer of specialized nerve cells that mediates vision and is located on the back of the...

‘Genetic Engineering & Biotechnology News’ highlights the problems insurers will face with regenerative medicine

It appears that Regenerative Times is not the only one thinking about how disruptive medicine 3.0 will be. Matthew Majweski at Genetic Engineering & Biotechnology News has written a report on similar lines, which may be interesting to readers of this blog, so we figured it was worth mention. The article highlights the fact that regenerative therapies will increase traditional...

Tufts University successfuly develops technique to regenerate functioning olfactory cells

Tufts University has reported a breakthrough that is likely to lead to a cure for those who have a diminished, or even lost sense of smell. The key was developing a method to mass produce the horizontal basal cells ( which further differentiate into multiple types of cells that make up the olfactory epithelium), and then activating them. Not only...
Invossa Vials

Invossa has lost it’s regulatory approval in South Korea

Today, Kolon Life Sciences ordered an emergency stop-sale on distribution and sales of their pioneering cartilage regeneration drug, Invossa. KLS CEO Lee Woo-suk held a press conference explaining the reason for the temporary withdrawal - an ingredient in Invossa's formulation was mislabeled as originating from a chondrocyte cell, instead of a kidney cell. This discrepancy...